This series focuses on targeted treatment approaches for patients with differentiated thyroid cancer.
EP. 1: Identifying NTRK and RET Alterations in Differentiated Thyroid Cancer
Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.
EP. 2: Challenges for Thyroid Cancer With RET and NTRK Alterations
Lova Sun, MD, discusses the importance of identifying genetic alterations in thyroid cancer, including RET and NTRK alterations.
EP. 3: Treatment Options for NTRK and RET Alterations in Thyroid Cancer
Lova Sun, MD, MSCE, discusses targeted therapies for NTRK and RET alterations in thyroid cancers.
EP. 4: Combating Resistance Mechanisms to Treatment in Thyroid Cancer
Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.
EP. 5: The Importance of Identifying Genetic Alterations in Thyroid Cancer
Lova Sun, MD, MCSE, assistant professor at the Hospital of the University of Pennsylvania, discusses the important of next-generation sequencing for patients with thyroid cancer.
EP. 6: Wirth Discusses SELECT Trial: Lenvatinib in RAI-Refractory DTC
Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.
EP. 7: Managing Lenvatinib’s Adverse Effects in RAI-Refractory DTC
Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.